DDInter1257 DDInter1376
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nalbuphine {u} (Compound) resembles {v} (Compound) Oxycodone
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxone
Nalbuphine {u} (Compound) resembles {v} (Compound) Hydromorphone
Nalbuphine {u} may lead to a major life threatening interaction when taken with {v} Morphine
Nalbuphine {u} (Compound) binds {v} (Gene) OPRD1
Nalbuphine {u} (Compound) upregulates {v} (Gene) GPATCH8
Nalbuphine {u} (Compound) is included by {v} (Pharmacologic Class) Competitive Opioid Antagonists
Nalbuphine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Nalbuphine {u} (Compound) causes {v} (Side Effect) Asthenia
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lindane
Nalbuphine (Compound) resembles Oxycodone (Compound)
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Nalbuphine (Compound) resembles Hydromorphone (Compound)
Nalbuphine may lead to a major life threatening interaction when taken with Morphine
Nalbuphine (Compound) binds OPRD1 (Gene)
Nalbuphine (Compound) upregulates GPATCH8 (Gene)
Nalbuphine (Compound) is included by Competitive Opioid Antagonists (Pharmacologic Class)
Nalbuphine (Compound) downregulates ATP6V1D (Gene)
Nalbuphine (Compound) causes Asthenia (Side Effect)
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Lindane